Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients

MicroRNAs (miRNAs) regulate gene expression in a tissue-specific manner. However, little is known about the miRNA expression changes induced by the therapy in rectal cancer (RC) patients. We evaluated miRNA expression levels before and after therapy and identified specific miRNA signatures reflectin...

Full description

Bibliographic Details
Main Authors: Klara Cervena, Vendula Novosadova, Barbara Pardini, Alessio Naccarati, Alena Opattova, Josef Horak, Sona Vodenkova, Tomas Buchler, Pavel Skrobanek, Miroslav Levy, Pavel Vodicka, Veronika Vymetalkova
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/full
id doaj-0fce0d73d1a041b9ac949c865103fdbc
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Klara Cervena
Klara Cervena
Vendula Novosadova
Barbara Pardini
Barbara Pardini
Alessio Naccarati
Alessio Naccarati
Alena Opattova
Alena Opattova
Alena Opattova
Josef Horak
Josef Horak
Sona Vodenkova
Sona Vodenkova
Tomas Buchler
Pavel Skrobanek
Miroslav Levy
Pavel Vodicka
Pavel Vodicka
Pavel Vodicka
Veronika Vymetalkova
Veronika Vymetalkova
Veronika Vymetalkova
spellingShingle Klara Cervena
Klara Cervena
Vendula Novosadova
Barbara Pardini
Barbara Pardini
Alessio Naccarati
Alessio Naccarati
Alena Opattova
Alena Opattova
Alena Opattova
Josef Horak
Josef Horak
Sona Vodenkova
Sona Vodenkova
Tomas Buchler
Pavel Skrobanek
Miroslav Levy
Pavel Vodicka
Pavel Vodicka
Pavel Vodicka
Veronika Vymetalkova
Veronika Vymetalkova
Veronika Vymetalkova
Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients
Frontiers in Oncology
biomarker
microRNA
liquid biopsy
plasma
miR-122-5p
miR-142-5p
author_facet Klara Cervena
Klara Cervena
Vendula Novosadova
Barbara Pardini
Barbara Pardini
Alessio Naccarati
Alessio Naccarati
Alena Opattova
Alena Opattova
Alena Opattova
Josef Horak
Josef Horak
Sona Vodenkova
Sona Vodenkova
Tomas Buchler
Pavel Skrobanek
Miroslav Levy
Pavel Vodicka
Pavel Vodicka
Pavel Vodicka
Veronika Vymetalkova
Veronika Vymetalkova
Veronika Vymetalkova
author_sort Klara Cervena
title Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients
title_short Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients
title_full Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients
title_fullStr Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients
title_full_unstemmed Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients
title_sort analysis of microrna expression changes during the course of therapy in rectal cancer patients
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-09-01
description MicroRNAs (miRNAs) regulate gene expression in a tissue-specific manner. However, little is known about the miRNA expression changes induced by the therapy in rectal cancer (RC) patients. We evaluated miRNA expression levels before and after therapy and identified specific miRNA signatures reflecting disease course and treatment responses of RC patients. First, miRNA expression levels were assessed by next-generation sequencing in two plasma samplings (at the time of diagnosis and a year after) from 20 RC patients. MiR-122-5p and miR-142-5p were classified for subsequent validation in plasma and plasma extracellular vesicles (EVs) on an independent group of RC patients (n=107). Due to the intrinsic high differences in miRNA expression levels between samplings, cancer-free individuals (n=51) were included in the validation phase to determine the baseline expression levels of the selected miRNAs. Expression levels of these miRNAs were significantly different between RC patients and controls (for all p <0.001). A year after diagnosis, miRNA expression profiles were significantly modified in patients responding to treatment and were no longer different from those measured in cancer-free individuals. On the other hand, patients not responding to therapy maintained low expression levels in their second sampling (miR-122-5p: plasma: p=0.05, EVs: p=0.007; miR-142-5p: plasma: p=0.008). Besides, overexpression of miR-122-5p and miR-142-5p in RC cell lines inhibited cell growth and survival. This study provides novel evidence that circulating miR-122-5p and miR-142-5p have a high potential for RC screening and early detection as well as for the assessment of patients’ outcomes and the effectiveness of treatment schedule.
topic biomarker
microRNA
liquid biopsy
plasma
miR-122-5p
miR-142-5p
url https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/full
work_keys_str_mv AT klaracervena analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT klaracervena analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT vendulanovosadova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT barbarapardini analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT barbarapardini analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT alessionaccarati analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT alessionaccarati analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT alenaopattova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT alenaopattova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT alenaopattova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT josefhorak analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT josefhorak analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT sonavodenkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT sonavodenkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT tomasbuchler analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT pavelskrobanek analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT miroslavlevy analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT pavelvodicka analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT pavelvodicka analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT pavelvodicka analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT veronikavymetalkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT veronikavymetalkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
AT veronikavymetalkova analysisofmicrornaexpressionchangesduringthecourseoftherapyinrectalcancerpatients
_version_ 1717815430118113280
spelling doaj-0fce0d73d1a041b9ac949c865103fdbc2021-09-04T06:01:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.702258702258Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer PatientsKlara Cervena0Klara Cervena1Vendula Novosadova2Barbara Pardini3Barbara Pardini4Alessio Naccarati5Alessio Naccarati6Alena Opattova7Alena Opattova8Alena Opattova9Josef Horak10Josef Horak11Sona Vodenkova12Sona Vodenkova13Tomas Buchler14Pavel Skrobanek15Miroslav Levy16Pavel Vodicka17Pavel Vodicka18Pavel Vodicka19Veronika Vymetalkova20Veronika Vymetalkova21Veronika Vymetalkova22Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaCzech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Prague, CzechiaMolecular Genetics Epidemiology Unit, Italian Institute for Genomic Medicine, c/o IRCCS Candiolo,, Turin, ItalyCandiolo Cancer Institute, FPO-IRCCS, Candiolo, ItalyMolecular Genetics Epidemiology Unit, Italian Institute for Genomic Medicine, c/o IRCCS Candiolo,, Turin, ItalyCandiolo Cancer Institute, FPO-IRCCS, Candiolo, ItalyDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaThird Faculty of Medicine, Charles University, Prague, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaDepartment of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, CzechiaDepartment of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, CzechiaDepartment of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, CzechiaInstitute of Biology and Medical Genetics, 1stMedical Faculty, Charles University, Prague, CzechiaBiomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, CzechiaMicroRNAs (miRNAs) regulate gene expression in a tissue-specific manner. However, little is known about the miRNA expression changes induced by the therapy in rectal cancer (RC) patients. We evaluated miRNA expression levels before and after therapy and identified specific miRNA signatures reflecting disease course and treatment responses of RC patients. First, miRNA expression levels were assessed by next-generation sequencing in two plasma samplings (at the time of diagnosis and a year after) from 20 RC patients. MiR-122-5p and miR-142-5p were classified for subsequent validation in plasma and plasma extracellular vesicles (EVs) on an independent group of RC patients (n=107). Due to the intrinsic high differences in miRNA expression levels between samplings, cancer-free individuals (n=51) were included in the validation phase to determine the baseline expression levels of the selected miRNAs. Expression levels of these miRNAs were significantly different between RC patients and controls (for all p <0.001). A year after diagnosis, miRNA expression profiles were significantly modified in patients responding to treatment and were no longer different from those measured in cancer-free individuals. On the other hand, patients not responding to therapy maintained low expression levels in their second sampling (miR-122-5p: plasma: p=0.05, EVs: p=0.007; miR-142-5p: plasma: p=0.008). Besides, overexpression of miR-122-5p and miR-142-5p in RC cell lines inhibited cell growth and survival. This study provides novel evidence that circulating miR-122-5p and miR-142-5p have a high potential for RC screening and early detection as well as for the assessment of patients’ outcomes and the effectiveness of treatment schedule.https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/fullbiomarkermicroRNAliquid biopsyplasmamiR-122-5pmiR-142-5p